Compare MXL & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXL | VIR |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2010 | 2019 |
| Metric | MXL | VIR |
|---|---|---|
| Price | $19.01 | $7.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $19.80 | ★ $28.63 |
| AVG Volume (30 Days) | 1.3M | ★ 1.9M |
| Earning Date | 01-29-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $467,641,000.00 | $16,860,000.00 |
| Revenue This Year | $18.98 | N/A |
| Revenue Next Year | $12.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 29.71 | N/A |
| 52 Week Low | $8.35 | $4.16 |
| 52 Week High | $20.82 | $10.67 |
| Indicator | MXL | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 54.03 |
| Support Level | $16.11 | $6.86 |
| Resistance Level | $18.27 | $7.97 |
| Average True Range (ATR) | 1.23 | 0.50 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 61.52 | 61.53 |
MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.